Navidea Biopharmaceuticals Inc EV/EBITDA
¿Qué es el EV/EBITDA de Navidea Biopharmaceuticals Inc?
El EV/EBITDA de Navidea Biopharmaceuticals Inc es N/A
¿Cuál es la definición de EV/EBITDA?
EV / EBITDA es el valor de la empresa dividido por las ganancias antes de intereses, impuestos, depreciación y amortización. Es una medida de cuál cara es una acción y es más frecuentemente válida para comparaciones entre compañías que la relación precio / ganancias. Mide el precio (en forma de valor empresarial) que un inversionista paga en beneficio del flujo de caja de la compañía (en forma de EBITDA).
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV/EBITDA de compañías en Sector Health Care en NYSEMKT en comparadas con Navidea Biopharmaceuticals Inc
¿Qué hace Navidea Biopharmaceuticals Inc?
navidea biopharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. it operates through two segments, diagnostic substances and therapeutic development programs. the company develops manocept platform to target the cd206 mannose receptor expressed on activated macrophages. its cd206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (pet), imaging and topical gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. further, the company offers nav4694, a fluorine-18 labeled pet imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of alzheimer's disease and mild cognitive impairment. in addition, it is de
Empresas con ev/ebitda similar a Navidea Biopharmaceuticals Inc
- Amigo PLC tiene EV/EBITDA de N/A
- Surgalign tiene EV/EBITDA de N/A
- Catasys tiene EV/EBITDA de N/A
- Goldhills tiene EV/EBITDA de N/A
- Just Kitchen tiene EV/EBITDA de N/A
- Alternate Health tiene EV/EBITDA de N/A
- Navidea Biopharmaceuticals Inc tiene EV/EBITDA de N/A
- Tombill Mines tiene EV/EBITDA de N/A
- Grand Talents tiene EV/EBITDA de N/A
- CV Sciences tiene EV/EBITDA de N/A
- Angold Resources tiene EV/EBITDA de N/A
- Adamis Pharmaceuticals Corp tiene EV/EBITDA de N/A
- Ovid Therapeutics Inc tiene EV/EBITDA de N/A